Previsioni

Acquista
  1
Mantieni
  0
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Virbac exceeds first-half sales forecasts and confirms 2026 targets

    In the first half Virbac reported sales of €768m (+7.4% currency-adjusted) and quarterly sales of €384m, slightly above the LSEG consensus estimate of €381m. Growth was driven mainly by volume and product mix (about 5.4 percentage points); price adjustments contributed roughly 2 percentage points. The company confirmed its 2026 targets: sales growth of 5.5–7.5% and an adjusted operating margin of around 17%. » Altro su de.investing.com


  • Virbac confirms full-year guidance after 7.7% sales rise in first quarter

    Virbac reports currency- and portfolio-adjusted sales growth of 7.7% in Q1, driven by strong North America business (+20.7%) and gains in international markets (+9.1%). Volume increases contributed around 6 percentage points to growth, price adjustments about 2%; exchange rates weighed with roughly -5.5%. The Thyronorm acquisition added about 1%; pet products and livestock showed double-digit and strong increases, while regulatory delays weighed on other businesses. Virbac confirms its full-year guidance of +5.5–7.5% sales growth at constant exchange rates, expects an adjusted EBITA margin of around 17% and cash generation of about €80m with capex of around €125m. » Altro su de.investing.com


  • Virbac records 7.9% organic growth in 2025 despite currency headwinds

    Virbac reports 2025 revenue of €1,464.7m (+8.7% nominal, +7.9% organic) and adjusted EBIT of €234.4m with a margin of 16.0%. Currency losses weighed on revenue and EBIT, while R&D spending rose to a record level (€115.1m) and the pipeline includes around 40 prioritized projects. North America was the strongest growth region at +14.7%; pets continue to account for the majority of sales (58.8%). The Thyronorm acquisition strengthens the endocrinology platform; management expects 2026 organic revenue growth of 5.5–7.5% and an adjusted EBIT margin of around 17%. » Altro su de.investing.com


  • Virbac reports 2025 revenue growth, operational pressures weigh on margins

    Virbac posted 2025 revenue of €1,464.7m (+7.9% currency- and portfolio-adjusted) and adjusted EBITA of €234.4m, corresponding to a margin of 16.3%, meeting guidance. Net profit rose 3.2% to €150.5m, while gross margin was hit by 0.7 percentage points due to a temporary halt in antigen production and higher inventory write-downs. R&D spending reached a record level, net debt stood at €172.8m, and a net dividend of €1.45 per share is planned for the annual general meeting. For 2026 Virbac confirms currency- and portfolio-adjusted revenue growth of 5.5–7.5% (including Thyronorm) and targets an adjusted EBITA margin of around 17%; US tariffs have already been factored in. » Altro su de.investing.com


  • Virbac soutenu par la recommandation positive d'Oddo BHF

    Virbac a enregistré une forte hausse en Bourse après qu'Oddo BHF a relevé sa recommandation de Neutre à Surperformance et augmenté son objectif de cours à 395 euros. Les analystes saluent la solidité des fondamentaux de Virbac et anticipent une amélioration de la marge opérationnelle d'ici 2030. Toutefois, le deuxième trimestre et le premier semestre 2025 seront affectés par une base de comparaison élevée, avec des perspectives plus favorables attendues à partir du troisième trimestre. » Altro su abcbourse.com

Nel 2026, Virbac ha già distribuito 1,45 € di dividendi. L'ultimo pagamento è avvenuto a luglio.

Dati finanziari

Nell'ultimo trimestre, Virbac ha registrato ricavi pari a 761,99 Mln € e un utile netto di 86,69 Mln €

(EUR) giugno 2026
YoY
Ricavi 761,99 Mln -
Utile lordo 278,39 Mln -
Utile netto 86,69 Mln -
EBITDA 165,66 Mln -

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
2,93 Mld €
Numero di azioni
8,38 Mln
Massimo/minimo a 52 settimane
397,64 € - 315,33 €
Rendimento da dividendo
0,41%
Dividendi TTM
1,45 €
Beta
0,78
Rapporto P/E
18,42
Rapporto PEG
1,08
Rapporto P/B
2,35
Rapporto P/S
1,92

Profilo aziendale

Virbac SA produce e commercializza una gamma di prodotti e servizi per animali da compagnia e animali da reddito destinati alla produzione alimentare in Francia, Europa, America Latina, Nord America, Asia Pacifico, Medio Oriente e Africa. L'azienda offre una gamma di vaccini, prodotti per l'igiene dentale, per la riproduzione, per la dermatologia, parassiticidi, prodotti diagnostici, antibiotici e prodotti per l'acquacoltura; nonché medicinali veterinari per anestesia, geriatria, comportamento e micronutrienti iniettabili, oltre ad alimenti per animali domestici e identificazione elettronica. Si rivolge a veterinari, agricoltori e proprietari di animali domestici. Virbac SA è stata fondata nel 1968 ed ha sede a Carros, in Francia.

Nome
Virbac
CEO
Paul Martingell
Sede centrale Carros, pa
Francia
Sito web
Quotazione in borsa
07/07/1992
Dipendenti 6442

Simboli di borsa

Borsa Simbolo
Euronext
VIRP.PA
Pnk
VRBCF
Frankfurt
V16.F
Düsseldorf
V16.DU
London
0NM7.L
Paris
VIRP.PA
München
V16.MU
SIX
VIRP.SW
🍪

Parqet  usa i cookie. Scopri di più